Summary
Identification of rare genetic variants associated with schizophrenia has proven challenging due to multiple sources of heterogeneity, which may be reduced in founder populations. We examined ultra-rare exonic variants in 786 patients with schizophrenia and 463 healthy comparison subjects, all drawn from the Ashkenazi Jewish population. Cases had a higher frequency of novel missense or loss of function (MisLoF) variants compared to controls. Characterizing 141 “case-only” genes (in which ≥ 3 cases in our dataset had MisLoF variants with none found in controls), we identified cadherins as a novel gene set associated with schizophrenia, including a recurrent mutation in PCDHA3. Modeling the effects of purifying selection demonstrated that deleterious ultra-rare variants are greatly over-represented in the Ashkenazi population, resulting in enhanced power for rare variant association. Identification of cell adhesion genes in the cadherin/protocadherin family helps specify the synaptic abnormalities central to the disorder, and suggests novel potential treatment strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge financial support from the following NIH research grants: AG042188 (GA) DK62429 DK062422 DK092235 (JHC) NS050487 NS060113 (LNC) AG021654 AG027734 (NB) MH089964 MH095458 MH084098 (TL) CA121852 (IP). We also acknowledge NSF research grants 08929882 and 0845677 (IP), and grants from the Rachel and Lewis Rudin Foundation (HE), the Northwell Health Foundation (TL), the Brain & Behavior Foundation (TL), the US-Israel Binational Science Foundation (TL, AD), the LUNGevity Foundation (ZHG), the New York Crohn's Disease Foundation (IPeter), the Edwin & Caroline Levy and Joseph & Carol Reich Foundation (SB), the Parkinson's Disease Foundation (LNC), the Sharon Levine Corzine Cancer Research Fund (KO), and the Andrew Sabin Family Research Fund (KO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sequenced samples (n=1346) were derived from subjects described previously from multiple case-control cohorts described in Supplementary Table 1. Informed consent was obtained in accordance with institutional policies and the studies were approved by the corresponding institutional review boards.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Additional data on relationship between common variant polygenic risk score and ultra-rare variant burden included.
Data Availability
Variant files will be made available through the European Genome-Phenome Archive (EGA) upon peer-reviewed publication, consistent with our prior work (https://ega-archive.org/datasets/EGAD00001000781).